BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
Cell & Gene Therapy Summit 2026
July 6 - July 8
Advancing the Path from Innovation to Commercially Viable Therapies
The Cell & Gene Therapy Summit 2026 brings together leaders from industry, academia, healthcare, and government to discuss the latest advancements in cell and gene therapy development, manufacturing, commercialization, and patient access.
This year’s summit focuses on advancing cell and gene therapies through innovation, technology, and collaboration, covering topics ranging from manufacturing and process development to regulatory strategy, commercialization, and market adoption. The event convenes experts across the therapeutic development lifecycle to address the challenges and opportunities shaping the future of advanced therapies.
Jennifer MacDonald, Chief Operating Officer of ARMI, will serve as a panelist during the session, “Creating a Commercially Viable Therapy.” The discussion will examine the critical factors required to successfully translate promising therapies from research and clinical development into scalable, commercially sustainable products capable of reaching patients.
ARMI’s participation reflects its commitment to advancing manufacturing innovation, strengthening supply chains, and addressing the practical challenges associated with scaling regenerative medicine and advanced therapy products.
Join leaders from across the cell and gene therapy community in Boston for three days of technical presentations, industry insights, networking, and collaboration.
